Daniel Weisdorf, MD
Interim Deputy Director and Interim Clinical Translational Research Services (CTRS) core Director
Dr. Daniel Weisdorf serves as CTSI's Interim Deputy Director and Director of its Clinical Translational Research Services (CTRS) core. As Interim Deputy Director Dr. Weisdorf works closely with the CTSI executive leadership team to oversee the institute’s operation and achieve excellence in clinical research. In his Interim CTRS Director role, he oversees the Clinical Research Support Center (CRSC) and teams that provide a wide range of services and expert consultations to support clinical and translational research. These teams bring expertise in areas such as biospecimen, biostatistics, protocol development, recruitment, regulatory affairs, and workforce development.
Dr. Weisdorf is Professor Emeritus in the Division of Hematology, Oncology and Transplantation at the University of Minnesota Medical School. While a Professor, he served as co-leader of the Transplant Biology and Therapy Program at the Masonic Cancer Center and Senior Research Advisor for the Center for International Blood and Marrow Transplant Research. His clinical and research interests are in application of blood and marrow transplant therapies for hematologic malignancies as well as extensive study of the clinical complications of transplantation including opportunistic infections and graft versus host disease (GVHD).
Dr. Weisdorf received his MD from the Chicago Medical School in 1975 and received Internal Medicine Training at Michael Reese Hospital in Chicago. He was a Fellow at the University of Minnesota in Hematology and Medical Oncology and is Board certified in both disciplines. Dr. Weisdorf previously served as CTSI Deputy Director, CTRS core Director, the Scientific Director of the National Marrow Donor Program, Senior Research Advisor for the Acute Leukemia Committee of the Center for International Blood & Marrow Transplant Research, and University of Minnesota Principal Investigator and Steering Committee chair of the NIH-sponsored Blood and Marrow Transplant Clinical Trials Network.